Polypharmacy in Psychiatry Practice, Volume I: Multiple Medication Use Strategies
Michael S Ritsner
Springer Science & Business Media, Feb 15, 2013 - Medical - 287 pages
Although monotherapy is generally recommended as the treatment of choice, treatment resistance of patients with psychosis, cognitive, mood and anxiety disorders represents a significant clinical problem. In this context, augmentation and combination strategies are commonly employed to address this problem. Although multiple medication use common in psychiatric practice, reasons, efficacy and safety for polypharmacy, and augmentative strategies have remained unclear. It remains unclear if there is an evidence base to support polypharmacy. Furthermore, excessive and inappropriate use of psychotropic medications has been recognized as a public health problem. This volume set is the first comprehensive, clinically oriented, reference on the multiple medication use to treat psychotic, cognitive, mood and anxiety disorders.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
Polypharmacy in Psychiatry Practice, Volume II: Use of Polypharmacy in the ...
Michael S Ritsner
No preview available - 2013
add-on adjunctive adverse amisulpride anticholinergic anticonvulsant antidepressants antipsy antipsychotic drugs antipsychotic monotherapy antipsychotic polypharmacy antipsychotic treatment aripiprazole associated atypical antipsychotic atypical antipsychotic medications augmentation benzodiazepines binding affinity Biol Psychiatry brain carbamazepine chotic chronic schizophrenia citalopram Clin Psychiatry Clin Psychopharmacol clozapine cognitive combination controlled trial CYP450 enzymes D2 receptors depressive symptoms dose double-blind drug interactions efficacy evidence extrapyramidal FGAs fluoxetine Fluvoxamine guidelines haloperidol improvement increased inhibition inpatients lamotrigine lithium mechanism of action Mental Health meta-analysis metabolism mg/day mirtazapine modafinil mood stabilizers MPMU Multiple Medication negative symptoms neuroleptic Neuropsychopharmacol Neurosci olanzapine pathophysiology patients with schizophrenia pharmacodynamic pharmacokinetic Pharmacol pharmacological placebo placebo-controlled potential prescribing prescription psychosis psychotic psychotropic medications Quetiapine randomized risk risperidone Ritsner Schizophr Res schizophrenia schizophrenia patients serotonin serotonin syndrome SGAs side effects significant somatic somatoform disorders SSRIs strategies symptoms of schizophrenia syndrome TCAs therapeutic therapy topiramate trazodone treat treatment of schizophrenia treatment-resistant valproate Ziprasidone